You are here

Cellgene

Celgene drug shown to be effective, safe in psoriasis trial

Reuters

Sun, 03/3/13 - 11:22 am

This Week in Biotech: Part 1

Motley Fool

Sun, 01/27/13 - 11:07 am

Will Celgene’s Top Institutional Shareholders BUY More After the Stock Buyback?

Wall Street Cheat Street

Sat, 06/16/12 - 12:44 pm

Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2) in Patients with Recurrent Follicular Lymphoma Presented at ASCO

Yahoo/Business Wire

Sun, 06/3/12 - 11:10 am

follicular lymphoma

Biotech: A “Stock Picker’s Delight,” Says Morgan Stanley

Barron's

Sat, 02/11/12 - 11:36 am

Gilead Sciences

Celgene International Sarl Releases Results of Phase II Study on Multiple Myeloma Patients

Trading Markets

Sat, 06/12/10 - 10:14 am

Multiple Myeloma

Data from Combination of REVLIMID® and Rituxan® in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma Presented at ASCO

Yahoo/BusinessWire

Sat, 06/5/10 - 09:59 am

non-Hodgkin's lymphoma

ASCO's Big Winner

Motley Fool

Tue, 06/2/09 - 05:44 pm

Cougar Biotechnology